Literature DB >> 15368317

Cytopathologic grading of hepatocellular carcinoma on fine-needle aspiration.

Piotr Kulesza1, Michael Torbenson, Sheila Sheth, Yener S Erozan, Syed Z Ali.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) is routinely graded histopathologically using a modified Edmondson system (ES). The cytologic grading of HCC has been used predominantly as an adjunct in differential diagnoses (i.e., to help distinguish HCC from other tumors as well as nonneoplastic lesions). However, there are unanswered questions regarding the reliability of the cytologic grading of HCC and its correlation with histologic follow-up.
METHODS: A total of 106 cases of HCC were identified in the authors' cytopathology files from 1977 to the present. Of these cases, 64 had either a core needle or excisional biopsy sample that was judged to be adequate for histologic grading. From each case smears were graded independently in a blinded fashion by two cytopathologists, and tissue slides were graded by a liver pathologist. The cytopathologists' grading was then adjudicated by considering the histologic diagnosis as the "truth standard". Finally, after the scores were calculated, a statistical analysis was performed to ascertain the accuracy of the cytopathologic grading.
RESULTS: The sensitivity for accurate grading was found to be highest for well differentiated (WD) lesions; the specificity was found to be highest for poorly differentiated (PD) HCC for both cytopathologists. Interobserver agreement was highest for WD HCC. WD HCC displayed cohesive fragments, often associated with characteristic vascular/endothelial patterns. In addition, moderately differentiated (MD) HCC demonstrated numerous single cells and atypical naked nuclei, usually with prominent nucleoli. PD HCC displayed loose nests and three-dimensional fragments (often gland-like), pleomorphism, macronucleoli, and focal necrosis.
CONCLUSIONS: In the authors' experience, the three-tier cytologic grading of HCC was found to be only moderately accurate. The accuracy of cytologic grading was reported to be high for WD/PD HCC and low for MD HCC. The architectural criteria appear to be more useful for WD HCC, whereas marked cellular pleomorphism is specific for PD HCC. The authors propose that a two-tier grading system may be more useful, given the recent studies of HCC recurrence.

Entities:  

Mesh:

Year:  2004        PMID: 15368317     DOI: 10.1002/cncr.20409

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  5 in total

Review 1.  Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation.

Authors:  Umberto Cillo; Tommaso Giuliani; Marina Polacco; Luz Maria Herrero Manley; Gino Crivellari; Alessandro Vitale
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

2.  Role of Diffusion Weighted Imaging (DWI) for Hepatocellular Carcinoma (HCC) Detection and its Grading on 3T MRI: A Prospective Study.

Authors:  Shiva Shankar; Naveen Kalra; Anmol Bhatia; Radhika Srinivasan; Paramjeet Singh; Radha K Dhiman; Niranjan Khandelwal; Yogesh Chawla
Journal:  J Clin Exp Hepatol       Date:  2016-09-01

3.  Preoperative assessment of hepatocellular carcinoma tumor grade using needle biopsy: implications for transplant eligibility.

Authors:  Timothy M Pawlik; Ana L Gleisner; Robert A Anders; Lia Assumpcao; Warren Maley; Michael A Choti
Journal:  Ann Surg       Date:  2007-03       Impact factor: 12.969

4.  Cytological Comparison between Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma by Image Analysis Software Using Touch Smear Samples of Surgically Resected Specimens.

Authors:  Sho Kitamura; Keita Kai; Mitsuo Nakamura; Tomokazu Tanaka; Takao Ide; Hirokazu Noshiro; Eisaburo Sueoka; Shinich Aishima
Journal:  Cancers (Basel)       Date:  2022-05-05       Impact factor: 6.639

5.  High expression of Snail and NF-κB predicts poor survival in Chinese hepatocellular carcinoma patients.

Authors:  Min Zhang; Xin Dong; Dengcai Zhang; Xiaojie Chen; Xinyu Zhu
Journal:  Oncotarget       Date:  2017-01-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.